Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
9 hedge funds and large institutions have $27.5M invested in Anebulo Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 9 → 9 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.07% less ownership
Funds ownership: 17.99% → 17.92% (-0.07%)
4% less capital invested
Capital invested by funds: $28.7M → $27.5M (-$1.2M)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$4.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$83.8K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$17.5K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$17.5K |
| 4 |
BlackRock
New York
|
-$1.12K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$834 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
2L
1
22NW LP
Seattle,
Washington
| $21.9M | – | – | – |
|
|
MP
2
Mangrove Partners
Greenwich,
Connecticut
| $2.73M | -$83.8K | -11,954 | -3% |
|
|
LCM
3
Laurion Capital Management
New York
| $1.51M | – | – | – |
|
|
IC
4
Ikarian Capital
Dallas,
Texas
| $1.16M | -$17.5K | -2,502 | -1% |
|
|
BFM
5
Boothbay Fund Management
New York
| $114K | -$17.5K | -2,502 | -13% |
|
|
6
BlackRock
New York
| $50K | -$1.12K | -160 | -2% |
|
|
7
UBS Group
Zurich,
Switzerland
| $6K | +$4.3K | +614 | +262% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| – | -$834 | -119 | -75% |
|
ANEB Hedge Fund Activity: Q3 2021 in Review
9 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q3 2021, worth a combined $27.5M — down 4.2% from $28.7M a quarter earlier.
Fund positioning in ANEB was balanced in Q3 2021: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 5 trimmed.
The largest buyer was UBS Group, adding an estimated $4.3K. The largest seller was Mangrove Partners, cutting an estimated $83.8K.
- 9 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $27.5M of Anebulo Pharmaceuticals stock for Q3 2021, down 4.2% quarter-over-quarter.
- 0 funds opened new Anebulo Pharmaceuticals positions in Q3 2021 and 0 closed out.
- The largest Anebulo Pharmaceuticals buyer in Q3 2021 was UBS Group, an estimated $4.3K added.
- The largest Anebulo Pharmaceuticals seller in Q3 2021 was Mangrove Partners, an estimated $83.8K sold.
Based on aggregated 13F filings for Q3 2021.